My Pathway: An Open Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib, and Vismodegib in Patients Who Have Advanced Cancer with Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents PRO-02

Diseases and Conditions Researched

Bladder; Brain and Nervous System; Breast - Female; Colon; Esophagus; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, skin; Other Endocrine System; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid

What is the purpose of this trial?

This is a multicenter, non-randomized, open-label study designed to evaluate fou r treatment regimens in patients with advanced cancer for whom there is no avail able, beneficial treatment. Patients with HER2 overexpression, amplification, or activating mutation will be treated with Herceptin/Perjeta; those with epiderm al growth factor receptor (EGFR), with Tarceva; those with BRAF-activating mutat ion, with Zelboraf; and those with Hedehog pathway potentially clinically releva nt mutation, with Erivedge. Treatment will continue until disease progression or unacceptable toxicity occurs. Study is expected to last up to 5 years.

Participation Guidelines

Age: Any

Click here for detailed participation information for this trial.

Sponsor: Genentech, Inc.
Last Updated:
Study HIC#: 1403013519